115761-61-0

Basic information

• Product Name: 1-(3-BIPHENYLYL)PIPERAZINE
• Synonyms: 1-(3-BIPHENYLYL)PIPERAZINE;1-(Biphenyl-3-yl)piperazine;1-(3-BIPHENYLYL)-PIPERAZINE >98%
• CAS NO: 115761-61-0
• Molecular Formula: C₁₆H₁₈N₂
• Molecular Weight: 238.33
• Product Categories: Piperaizine;piperazines
• Mol File: 115761-61-0.mol

Chemical Properties

• Melting Point: 69°C
• Boiling Point: 430.8 °C at 760 mmHg
• Flash Point: 198.4 °C
• Appearance: /
• Density: 1.068 g/cm³
• Vapor Pressure: 1.26E-07mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: 2-8°C
• PKA: 8.92±0.10(Predicted)
• CAS DataBase Reference: 1-(3-BIPHENYLYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-BIPHENYLYL)PIPERAZINE(115761-61-0)
• EPA Substance Registry System: 1-(3-BIPHENYLYL)PIPERAZINE(115761-61-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 115761-61-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-BIPHENYLYL)PIPERAZINE is used as a reactant for the preparation of aralkyl piperazine derivatives. These derivatives are designed to target serotonin reuptake inhibitory and 5-HT1A/5-HT7 receptors, which play a crucial role in the treatment of various psychiatric and neurological disorders, such as depression, anxiety, and schizophrenia. By modulating the activity of these receptors, 1-(3-BIPHENYLYL)PIPERAZINE and its derivatives can potentially improve the symptoms and management of these conditions.

InChI:InChI=1/C16H18N2/c1-2-5-14(6-3-1)15-7-4-8-16(13-15)18-11-9-17-10-12-18/h1-8,13,17H,9-12H2

Upstream product

• 2113-57-7 3-bromobiphenyl 
• 108-20-3 di-isopropyl ether 
• 2243-47-2 3-biphenyl amine 
• 334-22-5 N,N-bis(chloro-2-ethyl)amine 

Downstream Products

• 1610998-22-5 1-[5-(benzyloxy)-1H-indol-3-yl]-2-[4-(biphenyl-3-yl)piperazin-1-yl]ethane-1,2-dione 

Relevant articles and documents

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents

We developed a focused set of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6 Hz (32 mA) = 22.4 mg/kg, ED50 scPTZ = 59.4 mg/kg). In addition, 22 revealed potent efficacy in the formalin-induced tonic pain. These in vivo activities of 22 are likely mediated by several targets and may result from the inhibition of central sodium/calcium currents and transient receptor potential vanilloid 1 (TRPV1) receptor antagonism. Finally, the lead compound 22 revealed drug-like absorption, distribution, metabolism, excretion, toxicity (ADME-Tox) properties in the in vitro assays, making it a potential candidate for further development in epilepsy and neuropathic pain indications.

DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO

The invention relates to inhibitors of dihydrofolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. brucei, or L. major infections, using novel inhibitors of the invention.

COMPOSITIONS AND METHODS FOR TREATING INFECTIONS

The invention relates to inhibitors of dihydrotolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. hrucei, or L. major infections, using the novel inhibitors of the invention.

Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design

Current treatment of toxoplasmosis targets the parasite’s folate metabolism through inhibition of dihydrofolate reductase (DHFR). The most widely used DHFR antagonist, pyrimethamine, was introduced over 60 years ago and is associated with toxicity that can be largely attributed to a similar affinity for parasite and human DHFR. Computational analysis of biochemical differences between Toxoplasma gondii and human DHFR enabled the design of inhibitors with both improved potency and selectivity. The approach described herein yielded TRC-19, a promising lead with an IC50 of 9 nM and 89-fold selectivity in favor of Toxoplasma gondii DHFR, as well as crystallographic data to substantiate in silico methodology. Overall, 50% of synthesized in silico designs met hit threshold criteria of IC50 2-fold selectivity favoring Toxoplasma gondii, further demonstrating the efficiency of our structure-based drug design approach.

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

4-benzylpiperazines useful as neuroleptics

Compounds of formula (I) in which the broken line forms a phenyl, naphthyl, pyridyl, indolizine, pyrrolo[1,2-a]pyrazine, pyrrolo[1,2-a]pyrimidine or pyrrolo[1,2-c]pyrimidine ring-system, R=H, halogen, OH, alkyl, alkyloxy or alkylthio, R'=H, halogen, alkyl, alkyloxy, alkylthio, CN or CF3, n and p=1, 2 or 3, the alkyl radicals having 1 to 4 C in a straight or branched chain. These products are useful as neuroleptics. STR1